More Info on PreClinical Study on OBESITY
Positive
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semaglutide showed greater benefits in body weight and liver steatosis.
▪️Additive effects in reducing systemic inflammatory biomarkers with the combination therapy.
▪️Clear trend toward improved body composition with VTX3232 + semaglutide therapy.
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semaglutide showed greater benefits in body weight and liver steatosis.
▪️Additive effects in reducing systemic inflammatory biomarkers with the combination therapy.
▪️Clear trend toward improved body composition with VTX3232 + semaglutide therapy.
Negative
▪️Study results are preclinical and based on DIO mouse models, not human trials.
▪️Potential risks associated with translating preclinical findings to human trials.
免責事項：このコミュニティは、Moomoo Technologies Inc.が教育目的でのみ提供するものです。
さらに詳しい情報
コメント
サインインコメントをする
Spread kindness and love. Life is short. Don’t let greed eat you.
2557フォロワー
107フォロー中
28K訪問者
フォロー
72839823 : 株価が下がっている理由は何ですか？